The Office of Cancer Nanotechnology Research (OCNR) within the Center for Strategic Scientific Initiatives (CSSI) at the National Cancer Institute (NCI), develops and implements programs with and for the extramural research community related to the use of nanotechnology in medicine and cancer.
The OCNR leadership is staffed by a team of individuals whose collective backgrounds and expertise cover the broad multidisciplinary nature of cancer nanotechnology.
The mission of the Office of Cancer Nanotechnology Research is to strategically develop, fund, and administer initiatives aimed at solving modern oncology problems with nanotechnology solutions.
The overarching goal of these initiatives is to discover and develop innovative nanotechnologies for application(s), ranging from discovery through to clinical translation phases, for the delivery of innovative clinically relevant technologies aimed at cancer prevention, diagnosis, control, and treatment.
These initiatives include a programmatic effort known, collectively, as the NCI Alliance for Nanotechnology in Cancer, which aligns to several key areas of the National Cancer Institute’s existing priority areas.